Vir Biotechnology
251 hedge funds and large institutions have $1.25B invested in Vir Biotechnology in 2026 Q1 according to their latest regulatory filings, with 69 funds opening new positions, 117 increasing their positions, 41 reducing their positions, and 30 closing their positions.
185% more repeat investments, than reductions
Existing positions increased: 117 | Existing positions reduced: 41
130% more first-time investments, than exits
New positions opened: 69 | Existing positions closed: 30
80% more capital invested
Capital invested by funds: $698M → $1.25B (+$557M)
35% more call options, than puts
Call options by funds: $4.54M | Put options by funds: $3.36M
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
17.18% more ownership
Funds ownership: 83.24% → 100.42% (+17%)
15% more funds holding
Funds holding: 218 → 251 (+33)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$21.9M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$16M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$14M |
| 4 |
Goldman Sachs
New York
|
+$13.4M |
| 5 |
BlackRock
New York
|
+$13.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SIAU
SB Investment Advisers (UK)
London,
United Kingdom
|
-$17.3M |
| 2 |
O
OrbiMed
New York
|
-$14.4M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.66M |
| 4 |
Aberdeen Group
Edinburgh,
United Kingdom
|
-$8.39M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$8.25M |
VIR Hedge Fund Activity: Q1 2026 in Review
251 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Vir Biotechnology (VIR) for Q1 2026, worth a combined $1.25B — up 80% from $698M a quarter earlier.
Buyers outnumbered sellers: 69 funds opened new VIR positions and 30 closed out — a net gain of 39 holders — while 117 added to existing stakes and 41 trimmed.
The largest buyer was ADAR1 Capital Management, opening a new position worth an estimated $21.9M. The largest seller was SB Investment Advisers (UK), cutting an estimated $17.3M.
- 251 institutional investors held Vir Biotechnology (VIR) as of Q1 2026, up from 218 in Q4 2025.
- Funds reported $1.25B of Vir Biotechnology stock for Q1 2026, up 80% quarter-over-quarter.
- 69 funds opened new Vir Biotechnology positions in Q1 2026 and 30 closed out, a net change of +39 holders.
- The largest Vir Biotechnology buyer in Q1 2026 was ADAR1 Capital Management, an estimated $21.9M added.
- The largest Vir Biotechnology seller in Q1 2026 was SB Investment Advisers (UK), an estimated $17.3M sold.
Based on aggregated 13F filings for Q1 2026.